AIHealthcare

Guardant Health, Inc. is a publicly traded precision-oncology and molecular-diagnostics company that develops blood- and tissue-based liquid-biopsy tests, clinical-genomic data products, and AI-enabled analytics. Its offerings support cancer screening, treatment selection, recurrence and minimal-residual-disease monitoring, and biopharmaceutical research. The company’s AI healthcare activities are centered on its Smart Platform/InfinityAI capabilities, which use multiomic data—including genomic and epigenomic signals—to improve cancer classification, biomarker identification, therapy selection, and longitudinal disease monitoring. Guardant is a leading participant in the liquid-biopsy market, with products including Guardant360, Guardant Reveal, and Shield, and is listed on Nasdaq under GH.